Korea Q4 Roundup: GC’s IVIG US Approval, SK Biopharm Turns Around

Hanmi May Face Shareholders' Vote

Aside from mixed earnings at major South Korean pharma firms, recent updates across the local industry have included the ongoing leadership dispute at Hanmi Group, the approval and reimbursement of Yuhan’s lazertinib as a first-line NSCLC therapy and the US approval of GC Biopharma’s immuno-globulin product.

earnings
Yuhan's Lazertinib Reimbursed, Approved As 1L NSCLC Therapy • Source: Shutterstock

Major South Korean pharma firms reported largely mixed results in the fourth quarter amid a range of factors such as license deal-related income, robust sales of in-house developed prescription drugs and high margin products and solid overseas sales, as well as increased R&D spending as they focus more on innovative drug development.

More from South Korea

More from Focus On Asia

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By 

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.

AZ’s Oncology R&D Head On China’s Scientific Promise And True Innovation

 

AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.

Trump Tariffs – Indian Pharma Dodges Bullet, But Sword Still Hangs?

 
• By 

Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?